Systemic medications linked to an increased risk for skin malignancy

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Recent advancements in targeted therapies for cancer and inflammatory diseases have yielded significant clinical benefits.
• Widespread use of novel therapeutics targeting molecular pathways has raised concerns regarding potential adverse effects, particularly skin cancer.
• Specific drug classes, including BRAF inhibitors, sonic hedgehog inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase 5 (PDE-5) inhibitors, have been associated with increased skin cancer risk.

Purpose of the Study:

• To review the existing literature on the association between specific targeted drug classes and the development of skin malignancy.
• To consolidate information on the observed skin cancer risks associated with BRAF inhibitors, sonic hedgehog-inhibiting agents, JAK inhibitors, and PDE-5 inhibitors.
• To provide recommendations for drug use, patient surveillance, and management strategies for skin cancer in patients undergoing these treatments.

Main Methods:

• Comprehensive literature search of scientific databases for studies reporting skin cancer incidence in patients using BRAF inhibitors, sonic hedgehog inhibitors, JAK inhibitors, and PDE-5 inhibitors.
• Systematic review and synthesis of data regarding the types of skin malignancies observed, risk factors, and reported associations.
• Analysis of current clinical guidelines and expert recommendations for managing skin cancer risk in patients treated with these agents.

Main Results:

• Evidence indicates an elevated risk of skin cancer, including squamous cell carcinoma and basal cell carcinoma, in patients treated with BRAF inhibitors and JAK inhibitors.
• Sonic hedgehog inhibitors have also been linked to an increased incidence of non-melanoma skin cancers.
• While data is less robust for PDE-5 inhibitors, some studies suggest a potential association that warrants further investigation.

Conclusions:

• Certain targeted therapies used for malignancies and inflammatory conditions are associated with an increased risk of skin cancer.
• Close monitoring and proactive dermatological surveillance are crucial for patients receiving these medications.
• Adherence to recommended surveillance protocols and timely intervention are essential for managing skin cancer risk and ensuring optimal patient outcomes.